These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 15638855

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P, Sortino G, Giustolisi R.
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
    Bhatti SS, Kumar L, Dinda AK, Dawar R.
    Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E, Terpos E, Papaioannou M, Hatjileontis C, Kaloutsi V, Galaktidou G, Gerotziafas G, Christakis J, Zervas K.
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [Abstract] [Full Text] [Related]

  • 8. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
    Cibeira MT, Rozman M, Segarra M, Lozano E, Rosiñol L, Cid MC, Filella X, Bladé J.
    Cytokine; 2008 Mar; 41(3):244-53. PubMed ID: 18178097
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
    Alexandrakis MG, Passam FH, Sfiridaki A, Kandidaki E, Roussou P, Kyriakou DS.
    Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia.
    Zhelyazkova AG, Tonchev AB, Kolova P, Ivanova L, Gercheva L.
    Scand J Clin Lab Invest; 2008 Apr; 68(6):492-500. PubMed ID: 18609087
    [Abstract] [Full Text] [Related]

  • 15. Expression of hepatocyte growth factor and basic fibroblast growth factor as prognostic indicators in gastric cancer.
    Zhang W, Chu YQ, Ye ZY, Zhao ZS, Tao HQ.
    Anat Rec (Hoboken); 2009 Aug; 292(8):1114-21. PubMed ID: 19533745
    [Abstract] [Full Text] [Related]

  • 16. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W, Hattori Y, Hashiguchi A, Kondoh K, Hozumi N, Ikeda Y, Sakamoto M, Hata J, Yamada T.
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [Abstract] [Full Text] [Related]

  • 17. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG, Passam FH, Boula A, Christophoridou A, Aloizos G, Roussou P, Kyriakou DS.
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [Abstract] [Full Text] [Related]

  • 18. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
    Alexandrakis MG, Sfiridaki A, Miyakis S, Pappa C, Kandidaki E, Alegakis A, Margioris AN.
    Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170
    [Abstract] [Full Text] [Related]

  • 19. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy.
    Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Wellik LA, Fonseca R, Lust JA, Witzig TE, Kyle RA, Greipp PR, Rajkumar SV.
    Bone Marrow Transplant; 2004 Aug; 34(3):235-9. PubMed ID: 15170170
    [Abstract] [Full Text] [Related]

  • 20. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.
    Bremnes RM, Camps C, Sirera R.
    Lung Cancer; 2006 Feb; 51(2):143-58. PubMed ID: 16360975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.